NOW ENROLLING IN VITILIGO
For adults with active non-segmental vitiligo

PF-06700841 is an investigational oral/topical TYK2/JAK1 inhibitor.
PF-06653600 is an investigational oral JAK3/TEC inhibitor.
The kinase activity of Janus kinases (JAK1, JAK3, and TYK2) and TEC family of non-receptor tyrosine kinases may play a role in the pathophysiology of several autoimmune diseases.

This is a phase 2b, randomized, double-blind, placebo-controlled, multicenter, dose-ranging study evaluating the efficacy and safety profile of PF-06653600 with a partially blinded extension period to evaluate the efficacy and safety of PF-06653600 and oral PF-06700841 in the treatment of subjects with active non-segmental vitiligo.

Planned countries for recruitment include: Canada, Japan, and the United States.

STUDY DESIGN

CLINICAL ENDPOINTS

ELIGIBILITY CRITERIA

REQUEST INFORMATION

REFERENCES

© 2019 Pfizer Inc. All rights reserved. October 2019
NOW ENROLLING IN VITILIGO
For adults with active non-segmental vitiligo

PF-06700841 is an investigational oral/topical TYK2/JAK1 inhibitor. PF-06653600 is an investigational oral JAK3/TEC inhibitor. The kinase activity of Janus kinases (JAK1, JAK3, and TYK2) and TEC family of non-receptor tyrosine kinases may play a role in the pathophysiology of several autoimmune diseases.

This is a phase 2b, randomized, double-blind, placebo-controlled, multicenter, dose-ranging study evaluating the efficacy and safety profile of PF-06653600 with a partially blinded extension period to evaluate the efficacy and safety of PF-06653600 and oral PF-06700841 in the treatment of subjects with active non-segmental vitiligo.

Planned countries for recruitment include: Canada, Japan, and the United States.

STUDY DESIGN
CLINICAL ENDPOINTS

Primary endpoints:
- Percent change from baseline of Vitiligo Area Scoring Index (VASI) at week 24
- Number of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs) from baseline to week 56
- Number of subjects with change from baseline in laboratory test results at week 56
- Number of subjects reporting TEAEs and TESAEs from baseline to week 56
- Number of specific clinical laboratory abnormalities from baseline to week 56

Key selected secondary endpoints:
- Percentage of subjects achieving ≥50% improvement in VASI from baseline (VASI<50) at week 24
- Percent change from baseline in VASI at week 20
- Percent change from baseline in facial VASI at week 24
- Percent change from baseline in Vitiligo Extent Score (VES) at week 24
- Percent change from baseline in self-assessment VES (SA-VES) at week 24
- Absolute change from baseline in VASI at week 24
- Percentage of subjects achieving VASI<50 at week 20

Efficacy and safety of these compounds, for the uses identified within, have not been established and are currently under investigation. Regulatory approval of any of these compounds or uses is dependent on the completion of the study programs and review and approval by regulatory authorities.

This is not a complete representation of all Pfizer pipeline compounds. This information is current as of July 2019.

The clinical trial information is available at http://clinicaltrials.gov.

© 2019 Pfizer Inc. All rights reserved. October 2019
NOW ENROLLING IN VITILIGO

For adults with active non-segmental vitiligo

PF-06700841 is an investigational oral/topical TYK2/JAK1 inhibitor.

PF-06651600 is an investigational oral JAK3/TEC inhibitor.

The kinase activity of Janus kinases (JAK1, JAK3, and TYK2) and TEC family of non-receptor tyrosine kinases may play a role in the pathophysiology of several autoimmune diseases.

This is a phase 2b, randomized, double-blind, placebo-controlled, multicenter, dose-ranging study evaluating the efficacy and safety profile of PF-06651600 with a partially blinded extension period to evaluate the efficacy and safety of PF-06651600 and oral PF-06700841 in the treatment of subjects with active non-segmental vitiligo.

Planned countries for recruitment include: Canada, Japan, and the United States.

STUDY DESIGN

Key selected inclusion criteria

- 18 to 65 years of age at the time of informed consent with moderate to severe active non-segmental vitiligo.

CLINICAL ENDPOINTS

Key selected exclusion criteria

- History of HIV or positive HIV serology at screening.
- Infected with hepatitis B or hepatitis C viruses.
- Evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB).

ELIGIBILITY CRITERIA

Pfizer CT.gov
Call Center: 1-800-718-1021
ClinicalTrials.gov_inquiries@pfizer.com

© 2019 Pfizer Inc. All rights reserved. October 2019

Efficacy and safety of these compounds, for the uses identified within, have not been established and are currently under investigation. Regulatory approval of any of these compounds or uses is dependent on the completion of the study programs and review and approval by regulatory authorities.

This is not a complete representation of all Pfizer pipeline compounds. This information is current as of July 2019.

The clinical trial information is available at www.clinicaltrials.gov.